

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: IMAGIN MEDICAL INC. (the "Issuer").

Trading Symbol: IME

Number of Outstanding Listed Securities: 178,340,278

Date: May 31, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

See news releases issued by the Company on May 12, 14, 21 and 28, 2020.

2. Provide a general overview and discussion of the activities of management.

On May 12, 2020, in support of Bladder Cancer Awareness Month, the Company announced that it would be undertaking a number of efforts and activities to help raise awareness about bladder cancer. Among these, Imagin has created and will make available for free download, virtual backgrounds containing the bladder cancer awareness ribbon that can be used in popular online video meeting platforms.

On May 14, 2020, the company provided an update on the actions the Company has taken in response to the global COVID-19 pandemic.

Jim Hutchens, President & CEO of Imagin Medical reported that the Company has implemented emergency measures to decrease non-essential expenses in all areas of Imagin's business in order to extend Imagin's cash runway. Salaries have been reduced company-wide, and the Company has put a freeze on employee travel, and switched to virtual development and operational meetings.

On May 21, 2020, the Company announced that its contract design and development firm, Optel, Inc., had delivered the functional i/Blue™ Imaging Systems that will be used to conduct in vivo studies and virtual demonstrations for evaluation by leading urologists.

Two i/Blue System functional units were initially slated for a first-in-human study assessing the final product design. However, medical institutions have suspended the initiation of medical device clinical studies due to the COVID-19 pandemic. While Imagin will continue to pursue first-in-human studies when clinical trials are permitted to resume, potentially later this year, the Company is currently pursuing alternative, preclinical study options.

Other i/Blue functional units will be used for virtual investor presentation and private medical demonstrations and meetings to generate interest and obtain performance feedback.

On May 28, 2020, the Company reported financial results for the three months ended March 31, 2020, and summarized recent corporate developments which include closing an oversubscribed non-brokered private placement for gross proceeds of \$1,914,000 in January 2020.

The Company invited all interested parties to participate in a conference call held that day during which the results were discussed.

The full text of the news releases issued in May, 2020 as well as the quarterly financial statements for the three months ended March 31, 2020 are posted on www.sedar.com.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law. **N/A**
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. **N/A**
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship. **N/A**
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced. **N/A**
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship. **N/A**

8. Describe the acquisition of new customers or loss of customers. **N/A**
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks. **N/A**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **N/A**
11. Report on any labour disputes and resolutions of those disputes if applicable. **N/A**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings. **N/A**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **N/A**
14. Provide details of any securities issued and options or warrants granted (cancelled).

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	1,000,000	Shares issued pursuant to exercise of warrants at \$0.05	Add to working capital

*(1) State aggregate proceeds and intended allocation of proceeds. **N/A***

15. Provide details of any loans to or by Related Persons. **NIL**
16. Provide details of any changes in directors, officers or committee members. **NONE**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends. **N/A**

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 3, 2020.

John Vacha

Name of Director or Senior Officer

(sgd.) "John Vacha"

Signature

Chief Financial Officer

Official Capacity

Issuer Details Name of Issue IMAGIN MEDICAL INC.	For Month End May 31, 2020	Date of Report June 3, 2020
Issuer Address 600 – 890 Pender St.		
City/Province/Postal Code Vancouver, B.C. V6C 1J9	Issuer Fax No.	Issuer Telephone No. 833 246-2446
Contact Name JOHN VACHA	Contact Position CFO	Contact Telephone No. 833 246-2446
Contact Email Address jvacha@imaginmedical.com	Web Site Address http://imaginmedical.com	